186 related articles for article (PubMed ID: 24108104)
1. Widespread spinal cord transduction by intrathecal injection of rAAV delivers efficacious RNAi therapy for amyotrophic lateral sclerosis.
Wang H; Yang B; Qiu L; Yang C; Kramer J; Su Q; Guo Y; Brown RH; Gao G; Xu Z
Hum Mol Genet; 2014 Feb; 23(3):668-81. PubMed ID: 24108104
[TBL] [Abstract][Full Text] [Related]
2. Adeno-associated virus-delivered artificial microRNA extends survival and delays paralysis in an amyotrophic lateral sclerosis mouse model.
Stoica L; Todeasa SH; Cabrera GT; Salameh JS; ElMallah MK; Mueller C; Brown RH; Sena-Esteves M
Ann Neurol; 2016 Apr; 79(4):687-700. PubMed ID: 26891182
[TBL] [Abstract][Full Text] [Related]
3. In vivo genome editing improves motor function and extends survival in a mouse model of ALS.
Gaj T; Ojala DS; Ekman FK; Byrne LC; Limsirichai P; Schaffer DV
Sci Adv; 2017 Dec; 3(12):eaar3952. PubMed ID: 29279867
[TBL] [Abstract][Full Text] [Related]
4. Utilizing minimally purified secreted rAAV for rapid and cost-effective manipulation of gene expression in the CNS.
Goodwin MS; Croft CL; Futch HS; Ryu D; Ceballos-Diaz C; Liu X; Paterno G; Mejia C; Deng D; Menezes K; Londono L; Arjona K; Parianos M; Truong V; Rostonics E; Hernandez A; Boye SL; Boye SE; Levites Y; Cruz PE; Golde TE
Mol Neurodegener; 2020 Mar; 15(1):15. PubMed ID: 32122372
[TBL] [Abstract][Full Text] [Related]
5. Gene Therapy for ALS-A Perspective.
Cappella M; Ciotti C; Cohen-Tannoudji M; Biferi MG
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31500113
[TBL] [Abstract][Full Text] [Related]
6. The deletion of mutant SOD1 via CRISPR/Cas9/sgRNA prolongs survival in an amyotrophic lateral sclerosis mouse model.
Duan W; Guo M; Yi L; Liu Y; Li Z; Ma Y; Zhang G; Liu Y; Bu H; Song X; Li C
Gene Ther; 2020 Apr; 27(3-4):157-169. PubMed ID: 31819203
[TBL] [Abstract][Full Text] [Related]
7. Recombinant adeno-associated viral (rAAV) vectors mediate efficient gene transduction in cultured neonatal and adult microglia.
Su W; Kang J; Sopher B; Gillespie J; Aloi MS; Odom GL; Hopkins S; Case A; Wang DB; Chamberlain JS; Garden GA
J Neurochem; 2016 Jan; 136 Suppl 1(0 1):49-62. PubMed ID: 25708596
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic gene silencing delivered by a chemically modified small interfering RNA against mutant SOD1 slows amyotrophic lateral sclerosis progression.
Wang H; Ghosh A; Baigude H; Yang CS; Qiu L; Xia X; Zhou H; Rana TM; Xu Z
J Biol Chem; 2008 Jun; 283(23):15845-52. PubMed ID: 18367449
[TBL] [Abstract][Full Text] [Related]
9. Initial gene vector dosing for studying symptomatology of amyotrophic lateral sclerosis in non-human primates.
Jackson KL; Dayton RD; Fisher-Perkins JM; Didier PJ; Baker KC; Weimer M; Gutierrez A; Cain CD; Mathis JM; Gitcho MA; Bunnell BA; Klein RL
J Med Primatol; 2015 Apr; 44(2):66-75. PubMed ID: 25639184
[TBL] [Abstract][Full Text] [Related]
10. Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases.
Holm A; Hansen SN; Klitgaard H; Kauppinen S
RNA Biol; 2022; 19(1):594-608. PubMed ID: 35482908
[TBL] [Abstract][Full Text] [Related]
11. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes.
Foust KD; Nurre E; Montgomery CL; Hernandez A; Chan CM; Kaspar BK
Nat Biotechnol; 2009 Jan; 27(1):59-65. PubMed ID: 19098898
[TBL] [Abstract][Full Text] [Related]
12. Intravenous Infusion of AAV for Widespread Gene Delivery to the Nervous System.
Gessler DJ; Tai PWL; Li J; Gao G
Methods Mol Biol; 2019; 1950():143-163. PubMed ID: 30783972
[TBL] [Abstract][Full Text] [Related]
13. [SOD1 gene therapy delays ALS disease progression].
Forsberg K; Karlsborg M; Salvesen L; Svenstrup K; Winroth I; Berntsson H; M Andersen P
Lakartidningen; 2024 Apr; 121():. PubMed ID: 38666665
[TBL] [Abstract][Full Text] [Related]
14. Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system.
Zhang H; Yang B; Mu X; Ahmed SS; Su Q; He R; Wang H; Mueller C; Sena-Esteves M; Brown R; Xu Z; Gao G
Mol Ther; 2011 Aug; 19(8):1440-8. PubMed ID: 21610699
[TBL] [Abstract][Full Text] [Related]
15. Physical positioning markedly enhances brain transduction after intrathecal AAV9 infusion.
Castle MJ; Cheng Y; Asokan A; Tuszynski MH
Sci Adv; 2018 Nov; 4(11):eaau9859. PubMed ID: 30443600
[TBL] [Abstract][Full Text] [Related]
16. Viral vectors for gene delivery to the central nervous system.
Lentz TB; Gray SJ; Samulski RJ
Neurobiol Dis; 2012 Nov; 48(2):179-88. PubMed ID: 22001604
[TBL] [Abstract][Full Text] [Related]
17. Targeted gene silencing in the nervous system with CRISPR-Cas13.
Powell JE; Lim CKW; Krishnan R; McCallister TX; Saporito-Magriña C; Zeballos MA; McPheron GD; Gaj T
Sci Adv; 2022 Jan; 8(3):eabk2485. PubMed ID: 35044815
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of first-in-man intrathecal injection of human astrocytes (AstroRx®) in ALS patients: phase I/IIa clinical trial results.
Gotkine M; Caraco Y; Lerner Y; Blotnick S; Wanounou M; Slutsky SG; Chebath J; Kuperstein G; Estrin E; Ben-Hur T; Hasson A; Molakandov K; Sonnenfeld T; Stark Y; Revel A; Revel M; Izrael M
J Transl Med; 2023 Feb; 21(1):122. PubMed ID: 36788520
[TBL] [Abstract][Full Text] [Related]
19. rAAV Gene Therapy in a Canavan's Disease Mouse Model Reveals Immune Impairments and an Extended Pathology Beyond the Central Nervous System.
Ahmed SS; Schattgen SA; Frakes AE; Sikoglu EM; Su Q; Li J; Hampton TG; Denninger AR; Kirschner DA; Kaspar B; Matalon R; Gao G
Mol Ther; 2016 Jun; 24(6):1030-1041. PubMed ID: 27039844
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of a SOD1-targeting artificial miRNA delivered by AAV9 in mice are impacted by miRNA scaffold selection.
Chen SK; Hawley ZCE; Zavodszky MI; Hana S; Ferretti D; Grubor B; Hawes M; Xu S; Hamann S; Marsh G; Cullen P; Challa R; Carlile TM; Zhang H; Lee WH; Peralta A; Clarner P; Wei C; Koszka K; Gao F; Lo SC
Mol Ther Nucleic Acids; 2023 Dec; 34():102057. PubMed ID: 37928442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
